Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1985)	10/18/2007 9:35:48 AM
From: Jibacoa	Respond to of 3722

The general market seems ready to continue the DT after yesterday's intraday reversal. FLML has been forming a base at the $9 level after the last sell off on Aug 23 <g> bigcharts.marketwatch.com The short position came down some in the last month, but it is still > 6x its DAV The stock has had a good size drop since it left the 20 level in July. Revenues have increased at double digit for 4 consecutive Qs. The LTD is moderate & the EL for 2008 is around $0.15/shr vs the $1.60 estimated for 2007. Today it announced some positive news on its PI of FT-105 Flamel Technologies Announces Positive Results of a Phase I Trial of FT-105 Basal Insulin versus Lantus(R) Thursday October 18, 9:00 am ET LYON, France--(BUSINESS WIRE)--Flamel Technologies (NASDAQ:FLML) today announced positive preliminary Phase I data from a trial comparing the safety, tolerability, and long-acting activity of FT-105 versus Lantus®, an approved basal insulin. FT-105 is a long-acting recombinant insulin formulation that uses a new microparticulate adaptation of Flamel’s proprietary Medusa® nanoparticle delivery system. Results from the trial showed that FT-105 achieved a sustained release of recombinant human insulin over the course of the 36-hour pharmacodynamic study period. Pharmacokinetic results indicate that insulin concentrations were sustained for more than 48 hours in subjects following a single dose of FT-105. Less diurnal variation in insulin concentration was observed in subjects administered FT-105 compared with Lantus. FT-105 was well tolerated by subjects, especially with respect to local tolerance. No serious adverse events were reported and no patients withdrew from the study due to adverse events. Flamel is seeking a licensing partner for this product. Dr. Jonathan Levy, of the Oxford Centre for Diabetes, Endocrinology, and Metabolism commented, "These results demonstrated a sustained, dose-proportional release of recombinant human insulin. These results are promising in that they show that FT-105 provided insulin concentrations that remained stable for the full 48 hours of the study.” Snip It seems that it is worth to keep an eye on FLML.<g> bigcharts.marketwatch.com Will see if the present base will be good enough for a rally or if it will dip some more to the $5 level, from where it started its run in 2003.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1985)	10/18/2007 12:47:39 PM
From: Steve Lokness	Read Replies (1) \| Respond to of 3722

Bernard; DVAX has been sneaking up and at 5.50, I believe it resets to positive bullish signal in P&F three box charts. Getting very close to that - what does your magic charts say? steve

To: Jibacoa who wrote (1985)	11/6/2007 9:13:38 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

SQNM was up 11.57% & continued to do OK AHs.The volume was 200Ks above its ADV. bigcharts.marketwatch.com The stock closed at its intraday H & is starting to get off its near term DT coming from the )ct 17 H at 11.63 bigcharts.marketwatch.com SQNM will start tomorrow morning a workshop at the AMP meeting in los Angeles & is going to have an exhibition booth to provide information about its MassARRAY products & genomics analysis capabilities. I think I better buy back the shares that I had to sell because of my protective SL last month.<g> It also has announced that it will market its licensed nucleic acid-based technology under the brand “SEQureDx" & is making plans to commercialize its molecular diagnostic tests based on that technology for screening and detection of prenatal disorders like Rhesus D incompatibility, Fragile X, Hemophilia, & a test for common anueploidies, like Downs syndrome. The workshop, “Introducing the Dawn of a New Technology: Noninvasive Prenatal Diagnostics,” will be hosted by Steve Owings, V.P. for Commercial Development of Prenatal Diagnostics, & will include the following presentations: Fetal Nucleic Acids in Maternal Plasma as a New Platform for Noninvasive Prenatal Diagnosis Extraction & Enrichment Methods for Fetal DNA MassARRAY Technology: Past and Future Applications in Genetic Testing Strategies for Successful Noninvasive Prenatal Testing: Fetal Identifiers and Workshop Summary SQNM is building a menu of prenatal tests with this technology, and expects the near-term commercial introduction of the first laboratory test to detect Rh incompatibility.It also will provide an update on its strategy for a noninvasive detection of Down syndrome. If the stock can close above $11 tomorrow, it should be a ble to resume its Sep-Oct UT, but don't expect another double that fast.<g> bigcharts.marketwatch.com Although the long term chart still looks "interesting" & it certainly has plenty of room to run.<g> bigcharts.marketwatch.com Bernard